By Yannis Jemiai, Chief Scientific Officer, Cytel
C-Suite and R&D Decision-Makers are always striving to make evidence-driven decisions. Yet the rules by which evidence is evaluated can bias these decisions, even when the method of decision-making seems objective. Our Chief Scientific Officer, Dr. Yannis Jemiai, has worked extensively on how to operationalize decision theoretic tools for clinical development decision-making. Here he introduces three quantitative frameworks that life-sciences decision-makers can quickly incorporate into their selection process when selecting an optimal design for their next clinical trial.